Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | ADCs in the management of urothelial carcinoma

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, highlights emerging therapies in the management of urothelial carcinoma, including antibody-drug conjugates (ADCs) such as enfortumab vedotin evaluated as a single agent, as well as in combination with pembrolizumab, and the anti-TROP2 therapy, sacituzumab govetican. In addition, Dr Loriot highlights disitamab vedotin, is a novel anti-HER2 ADC under clinical evaluation in patients with urothelial carcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.